SG10202113286RA - [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor - Google Patents
[1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptorInfo
- Publication number
- SG10202113286RA SG10202113286RA SG10202113286RA SG10202113286RA SG10202113286RA SG 10202113286R A SG10202113286R A SG 10202113286RA SG 10202113286R A SG10202113286R A SG 10202113286RA SG 10202113286R A SG10202113286R A SG 10202113286RA SG 10202113286R A SG10202113286R A SG 10202113286RA
- Authority
- SG
- Singapore
- Prior art keywords
- triazolo
- affinity
- type
- pyrimidine derivatives
- cannabinoid receptor
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 title 1
- 108050007331 Cannabinoid receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16175924 | 2016-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202113286RA true SG10202113286RA (en) | 2021-12-30 |
Family
ID=56203225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809678VA SG11201809678VA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
SG10202113286RA SG10202113286RA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809678VA SG11201809678VA (en) | 2016-06-23 | 2017-06-20 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Country Status (24)
Country | Link |
---|---|
US (1) | US10457685B2 (fr) |
EP (2) | EP4108665A1 (fr) |
JP (2) | JP6962942B2 (fr) |
KR (2) | KR102530131B1 (fr) |
CN (4) | CN115093418A (fr) |
AR (1) | AR108845A1 (fr) |
AU (2) | AU2017283136C1 (fr) |
BR (1) | BR112018075143A2 (fr) |
CA (2) | CA3206921A1 (fr) |
CL (1) | CL2018003610A1 (fr) |
CO (1) | CO2018011231A2 (fr) |
CR (2) | CR20180615A (fr) |
IL (2) | IL292015B1 (fr) |
MA (1) | MA45442A (fr) |
MX (1) | MX2018014684A (fr) |
MY (1) | MY197244A (fr) |
PE (1) | PE20190109A1 (fr) |
PH (1) | PH12018502733A1 (fr) |
RU (1) | RU2741597C2 (fr) |
SG (2) | SG11201809678VA (fr) |
TW (2) | TWI824380B (fr) |
UA (1) | UA123834C2 (fr) |
WO (1) | WO2017220517A1 (fr) |
ZA (1) | ZA201807133B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018015088A1 (fr) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de triazolo[4,5-d]pyrimidine |
WO2017220544A1 (fr) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine |
CN109415366B (zh) | 2016-06-23 | 2022-02-22 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
CN113387845B (zh) * | 2021-07-16 | 2022-12-20 | 国药集团化学试剂有限公司 | 一种苯甲基磺酰氟的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028557A1 (fr) * | 1999-10-18 | 2001-04-26 | University Of Connecticut | Derives indoliques cannabimimetiques |
WO2006051704A1 (fr) * | 2004-11-15 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | Composé imine |
EP1863778B1 (fr) | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Antagonistes du recepteur de la thrombine spirocyclique |
FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
RU2424242C2 (ru) * | 2006-03-30 | 2011-07-20 | Айрм Ллк | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 |
JP5583694B2 (ja) * | 2009-01-05 | 2014-09-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するピロリジン化合物 |
EP2311443A1 (fr) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Composition pharmaceutique contenant des antagonistes de récepteur de cannabinoïde-2 |
CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
CA2897513C (fr) | 2013-03-07 | 2021-03-16 | F. Hoffmann-La Roche Ag | Derives pyrazoles |
DK2991988T3 (en) * | 2013-05-02 | 2017-08-21 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
LT2991987T (lt) | 2013-05-02 | 2018-08-10 | F. Hoffmann-La Roche Ag | Purino dariniai kaip cb2 receptorių antagonistai |
ES2714094T3 (es) | 2013-09-06 | 2019-05-27 | Hoffmann La Roche | Derivados de triazolo[4,5-d]pirimidina como antagonistas del receptor cb2 |
KR20170078781A (ko) | 2014-11-07 | 2017-07-07 | 에프. 호프만-라 로슈 아게 | 칸나비노이드 수용체 2 작용제로서 트라이아졸로[4,5-d]피리미딘 |
WO2017220544A1 (fr) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de [1,2,3]triazolo[4,5-d]pyrimidine |
WO2018015088A1 (fr) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Nouveaux dérivés de triazolo[4,5-d]pyrimidine |
CN109415366B (zh) | 2016-06-23 | 2022-02-22 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
-
2017
- 2017-06-20 CN CN202210807089.7A patent/CN115093418A/zh active Pending
- 2017-06-20 BR BR112018075143-0A patent/BR112018075143A2/pt not_active Application Discontinuation
- 2017-06-20 PE PE2018003112A patent/PE20190109A1/es unknown
- 2017-06-20 CR CR20180615A patent/CR20180615A/es unknown
- 2017-06-20 SG SG11201809678VA patent/SG11201809678VA/en unknown
- 2017-06-20 MX MX2018014684A patent/MX2018014684A/es unknown
- 2017-06-20 MY MYPI2018002797A patent/MY197244A/en unknown
- 2017-06-20 JP JP2018566249A patent/JP6962942B2/ja active Active
- 2017-06-20 KR KR1020187037004A patent/KR102530131B1/ko active IP Right Grant
- 2017-06-20 IL IL292015A patent/IL292015B1/en unknown
- 2017-06-20 CA CA3206921A patent/CA3206921A1/fr active Pending
- 2017-06-20 RU RU2018146657A patent/RU2741597C2/ru active
- 2017-06-20 UA UAA201900294A patent/UA123834C2/uk unknown
- 2017-06-20 EP EP22174808.0A patent/EP4108665A1/fr active Pending
- 2017-06-20 EP EP17731149.5A patent/EP3475282B1/fr active Active
- 2017-06-20 SG SG10202113286RA patent/SG10202113286RA/en unknown
- 2017-06-20 CR CR20220661A patent/CR20220661A/es unknown
- 2017-06-20 CN CN201780036295.XA patent/CN109348716A/zh active Pending
- 2017-06-20 KR KR1020237014572A patent/KR20230062680A/ko active IP Right Grant
- 2017-06-20 MA MA045442A patent/MA45442A/fr unknown
- 2017-06-20 WO PCT/EP2017/064994 patent/WO2017220517A1/fr active Application Filing
- 2017-06-20 AU AU2017283136A patent/AU2017283136C1/en active Active
- 2017-06-20 CN CN202111184338.3A patent/CN113943297A/zh active Pending
- 2017-06-20 CN CN202210799583.3A patent/CN115073476A/zh active Pending
- 2017-06-20 CA CA3023043A patent/CA3023043A1/fr active Pending
- 2017-06-21 AR ARP170101708A patent/AR108845A1/es unknown
- 2017-06-22 TW TW111101354A patent/TWI824380B/zh active
- 2017-06-22 TW TW106120830A patent/TWI764908B/zh active
-
2018
- 2018-10-19 CO CONC2018/0011231A patent/CO2018011231A2/es unknown
- 2018-10-25 ZA ZA2018/07133A patent/ZA201807133B/en unknown
- 2018-11-01 IL IL262711A patent/IL262711B2/en unknown
- 2018-12-14 CL CL2018003610A patent/CL2018003610A1/es unknown
- 2018-12-20 US US16/228,539 patent/US10457685B2/en active Active
- 2018-12-21 PH PH12018502733A patent/PH12018502733A1/en unknown
-
2021
- 2021-07-26 AU AU2021206925A patent/AU2021206925B2/en active Active
- 2021-10-14 JP JP2021168709A patent/JP7308246B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201905456B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
HK1245764A1 (zh) | 3-取代的5-氨基-6h-噻唑並[4,5-d]嘧啶-2,7-二酮化合物 | |
DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物 | |
IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
HRP20190361T1 (hr) | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora | |
IL262711B1 (en) | History of a [3,2,1]triazolo[5,4-d]pyrimidine with affinity for the type 2 cannabinoid receptor | |
EP3452481A4 (fr) | Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux | |
ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound | |
HK1259613A1 (zh) | 新型5h-吡咯並[2,3-d]嘧啶-6(7h)-酮衍生物 | |
ZA202100259B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
ZA201804619B (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
EP3814356A4 (fr) | Dérivés de triazolotriazine en tant qu'antagonistes du récepteur a2a | |
EP3814355A4 (fr) | Dérivés de triazolotriazine en tant qu'antagonistes du récepteur a2a |